Want to see CH:DOCM full AI Analyst Report?
DOCM Stock Chart & Stats
CHF6.61
CHF0.36(1.86%)
At close: 4:00 PM EST
CHF6.61
CHF0.36(1.86%)
Day’s Range― - ―
52-Week RangeCHF3.92 - CHF9.24
Previous CloseN/A
Volume45.75K
Average Volume (3M)342.18K
Market Cap
CHF428.20M
Enterprise ValueCHF581.69M
Total Cash (Recent Filing)CHF149.92M
Total Debt (Recent Filing)CHF288.64M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding52,400,000
10 Day Avg. Volume377,518
30 Day Avg. Volume342,178
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.75
Price to Sales (P/S)0.27
P/FCF Ratio-3.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF6.50Price Target Upside-1.66% Downside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-1.8
Revenue Forecast (FY)CHF1.22B
Bulls Say, Bears Say
Bulls Say
High‑margin Digital Services GrowthDigital Services' 110% growth and strong margin contribution indicate a scalable, high‑return revenue stream (TeleClinic + Retail Media). Over the medium term, these higher‑margin services can expand CM3, improve group gross margins and materially support the path to EBITDA and FCF breakeven.
Large Customer Base And TeleClinic ScaleAn 11m active customer base and TeleClinic scale create durable cross‑sell and network advantages. Higher frequency (4.0x) and repeat rates (~77%) plus TeleClinic take‑rate revenue enable sustained LTV improvements and lower marginal acquisition cost, supporting long‑term revenue durability.
Improved Liquidity And LeverageA CHF160m liquidity buffer, lower net debt and roughly 50% equity ratio materially increase near‑term financial flexibility. This improved capital structure extends runway for executing the profitability roadmap, funding digital investments and absorbing one‑offs without immediate refinancing pressure.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent and worsening negative operating and free cash flow (-~88M OCF, -~90M FCF in 2025) erode liquidity over time and create dependency on external funding if structural improvement lags. This undermines capital allocation flexibility and raises refinancing and execution risk before sustained profitability.
Large Adjusted EBITDA LossesMaterial adjusted EBITDA losses (~CHF -48m in FY2025) and negative net margins in recent years reflect an ongoing inability to convert revenue into operating profit. Without consistent margin expansion, losses will continue to pressure returns, cash generation and the company's ability to self‑fund growth.
Logistics And Working‑capital InefficienciesInventory overstock (~CHF11m) and CHF9m receivables issues, combined with rising logistics costs, weaken cash conversion and increase operating volatility. These structural inefficiencies inflate working capital needs and can persistently depress free cash flow and margin recovery absent process fixes.
DOCM FAQ
What was DocMorris AG’s price range in the past 12 months?
DocMorris AG lowest stock price was CHF3.92 and its highest was CHF9.23 in the past 12 months.
What is DocMorris AG’s market cap?
DocMorris AG’s market cap is CHF428.20M.
When is DocMorris AG’s upcoming earnings report date?
DocMorris AG’s upcoming earnings report date is Aug 19, 2026 which is in 48 days.
How were DocMorris AG’s earnings last quarter?
Currently, no data Available
Is DocMorris AG overvalued?
According to Wall Street analysts DocMorris AG’s price is currently Overvalued.
Does DocMorris AG pay dividends?
DocMorris AG does not currently pay dividends.
What is DocMorris AG’s EPS estimate?
DocMorris AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does DocMorris AG have?
DocMorris AG has 52,400,000 shares outstanding.
What happened to DocMorris AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of DocMorris AG?
Currently, no hedge funds are holding shares in CH:DOCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DocMorris AG
DocMorris AG is a key player in the pharmaceutical sector, focusing on both online pharmacy services and the wholesale supply of medical and pharmaceutical goods. The company provides a comprehensive selection of items, including prescription and over-the-counter medications, health and wellness products, beauty and personal care lines, dietary supplements, pain relief remedies, and emergency first aid supplies. Furthermore, it offers specialized medication management support. In addition to its significant digital footprint, DocMorris AG also operates traditional brick-and-mortar pharmacy locations. Its commercial activities extend across Switzerland and into various international territories, serving medical practitioners, other online pharmaceutical distributors, and individual consumers directly. Notable brands within its portfolio include Zur Rose, PromoFarma, TeleClinic, and DocMorris. Established in 1993 and based in Frauenfeld, Switzerland, the company adopted its current name, DocMorris AG, in May 2023, having previously been known as Zur Rose Group AG.
DOCM Stock 12 Month Forecast
Average Price Target
CHF6.50
▼(-1.66% Downside)
Technical Analysis
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Galenica AG
―
Galderma Group AG
―
medmix AG
―
Options Prices
Currently, No data available
---